2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Tuesday, November 12, 2019

9:00AM-11:00AM: Abstract Number: 1959

Pleiotropy of Systemic Lupus Erythematosus (SLE) Risk Alleles: Association with Increased Risk for Type 1 Diabetes (T1D) Complications Through a PTPN22 Polymorphism

Genetics, Genomics & Proteomics Poster

9:00AM-11:00AM: Abstract Number: 1945

Polymorphisms in Genes Involved in Methotrexate Pathway: Predictor of Response to Methotrexate Therapy in Indian Rheumatoid Arthritis Patients

Genetics, Genomics & Proteomics Poster

9:00AM-11:00AM: Abstract Number: 2245

Polymyositis (PM) and Dermatomyositis (DM) Symptom Flares and Associated Impact from the Patient Perspective

Patient Outcomes, Preferences, & Attitudes Poster II: Patient Preferences, Beliefs, & Experiences

9:00AM-11:00AM: Abstract Number: 2566

Polypharmacy and Potentially Inappropriate Medication Use in Young versus Older Adults with SLE

SLE – Clinical Poster III: Treatment

9:00AM-11:00AM: Abstract Number: 2077

Population Impact Attributable to Modifiable Risk Factors for Hyperuricemia and the Fallacy of the Variance Explained

Epidemiology & Public Health Poster III: OA, Gout, & Other Diseases

9:00AM-11:00AM: Abstract Number: 2549

Population Pharmacokinetics of Atacicept in Systemic Lupus Erythematosus (SLE) – an Analysis of Three Clinical Trials

SLE – Clinical Poster III: Treatment

9:00AM-11:00AM: Abstract Number: 2261

Post Traumatic Stress Disorder in Patients with Rheumatoid Arthritis

Patient Outcomes, Preferences, & Attitudes Poster II: Patient Preferences, Beliefs, & Experiences

9:00AM-11:00AM: Abstract Number: 2372

Post-Approval Comparative Safety Study of Tofacitinib and Biologic DMARDs: Five‑Year Results from a US-based Rheumatoid Arthritis Registry

RA – Treatments Poster III: Safety and Outcomes

9:00AM-11:00AM: Abstract Number: 1983

Preclinical Evaluation of Targeting TGF-beta Signaling and Senescence in ex Vivo Models of Human Knee and Spine Osteoarthritis

Osteoarthritis & Joint Biology – Basic Science Poster

9:00AM-11:00AM: Abstract Number: 2499

Predicting Risk of Developing Psoriatic Arthritis (PsA) in Siblings of Patients with Psoriatic Arthritis

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Psoriatic Arthritis, Clinical Features

9:00AM-11:00AM: Abstract Number: 2390

Prediction of Disease Relapses by Multi-biomarker Disease Activity Score and Autoantibody Status in RA Patients Tapering DMARD Treatment in Stable Remission

RA – Treatments Poster III: Safety and Outcomes

9:00AM-11:00AM: Abstract Number: 2335

Prediction of Myocardial Fibrosis in Rheumatoid Arthritis Assessed by Cardiac Magnetic Resonance Imaging Using Artificial Neural Networks Models

RA – Diagnosis, Manifestations, & Outcomes Poster III: Comorbidities

9:00AM-11:00AM: Abstract Number: 2625

Predictors of Advanced Chronic Kidney Disease in Patients with ANCA Vasculitis and Renal Involvement

Vasculitis – ANCA-Associated Poster I

9:00AM-11:00AM: Abstract Number: 2491

Predictors of DAPSA28 Remission at 6 Months in Bio-Naive Patients with Psoriatic Arthritis Starting a TNF Inhibitor in Clinical Practice– Results from the EuroSpA Collaboration

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Psoriatic Arthritis, Clinical Features

9:00AM-11:00AM: Abstract Number: 2719

Predictors of Health Care Transition Practices Among North American Pediatric Rheumatology Providers

Pediatric Rheumatology – ePoster III: Systemic JIA, Fever, & Vasculitis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].